PeptideKey News
FDA approves Compass Pathways' COMP360 psilocybin for treatment-resistant depression — first psychedelic medicine in 70 years. Parallels to peptide reform.
This article is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.